New data boosts Novo against Sanofi in insulin-market fight

Carly Helfand

Nordisk has some new in hand that could help a safety advantage make its way onto the label of new drug Tresiba–and win it points heavyweight rival . In a recent study, the med hit its primary endpoint, cutting the number of hypoglycemic events by 30% compared with the French drugmaker's Lantus. 

FiercePharma News

Share This Post

Related Articles

Leave a Reply

© 2018 Global Regulatory Science. All rights reserved. Site Admin · Entries RSS · Comments RSS